Amneal Pharmaceuticals, Inc. reports developments across a diversified pharmaceutical business built around Affordable Medicines, Specialty and AvKARE. Its updates commonly cover U.S. launches of complex generics, injectables, biosimilars and other affordable medicines, including respiratory inhalation and ophthalmic products, as well as branded specialty treatments in neurology and endocrinology.
News about AMRX also includes clinical and regulatory disclosures for products such as CREXONT for Parkinson’s disease, financial results, capital-structure updates, material agreements and governance matters. AvKARE-related updates center on distribution of pharmaceuticals and medical products to U.S. federal, retail and institutional customers.
Amneal Pharmaceuticals (NYSE: AMRX), based in Bridgewater, NJ, is a fully-integrated pharmaceutical company engaged in developing, manufacturing, and distributing generic and specialty drugs. With a portfolio of around 250 product families, the company also focuses on complex dosage forms and branded products in central nervous system and endocrine disorders. Owning 65% of AvKARE, Amneal primarily serves governmental agencies, including the Department of Defense and Veterans Affairs. The company is expanding its reach across North America, Asia, and Europe to deliver high-quality medicines.
Amneal Pharmaceuticals (NYSE: AMRX) and PL Developments have begun shipping store brand equivalent Voltaren® Arthritis Pain Gel (diclofenac sodium topical gel, 1%) in various sizes after receiving FDA clearance. This product, previously available only by prescription, is significant for US consumers. The original Voltaren® Arthritis Pain generated approximately $250 million in sales prior to its switch to OTC in February 2020. This collaboration aims to enhance the availability of affordable generic medicines, demonstrating Amneal's commitment to accessible healthcare.